Valeritas is a medical technology company developing solutions for people with diabetes. It offers a V-Go wearable insulin delivery device (V-Go) for the delivery of basal-bolus insulin therapy in adults with Type 2 diabetes. V-Go provides a continuous preset basal rate of insulin and allows for on-demand bolus dosing around mealtimes, serving as an alternative to taking multiple daily insulin injections.

Employee Rating

3.4More
StateClosed
TypeSubsidiary
Parent CompanyZealand Pharma
Founded2006
Websitevaleritas.com
Cybersecurity ratingAMore
Valeritas was founded in 2006

Viewing summary data as a guest

Sign up for free to see all data

Key People/Management at Valeritas

Emmanuel Dulac

Emmanuel Dulac

President and Chief Executive Officer
Matt Dallas

Matt Dallas

Senior Vice President and Chief Financial Officer
Adam Steensberg

Adam Steensberg

Executive Vice President, Research & Development, and Chief Medical Officer
Frank Sanders

Frank Sanders

President of Zealand Pharma U.S.
Show more

Valeritas Financials and Metrics

Summary Metrics

Founding Date

2006

Total Funding

$272 m

Investors

Valeritas is a subsidiary of Zealand Pharma

Valeritas Cybersecurity Score

Cybersecurity ratingPremium dataset

A

91/100

SecurityScorecard logo

Valeritas Online and Social Media Presence

Embed Graph

Valeritas Frequently Asked Questions

  • When was Valeritas founded?

    Valeritas was founded in 2006.

  • Who are Valeritas key executives?

    Valeritas's key executives are Emmanuel Dulac, Matt Dallas and Adam Steensberg.

  • How many employees does Valeritas have?

    Valeritas has 90 employees.

  • Who are Valeritas competitors?

    Competitors of Valeritas include Genteel, Neurometrix and Reapplix.